Metropolis Healthcare Limited
₹545.15-₹8.85 (-1.6%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹9,882 Cr
- P/E
- 74.0x
- EV / EBITDA
- 36.5x
- Revenue
- ₹1,217 Cr
- Net margin
- 10.5%
- ROCE
- 21.5%
Price chart
Technical chartScreen technicals →+11.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +0.6%
- 3M
- -6.9%
- 6M
- +14.3%
- 1Y
- +11.1%
- 5Y
- -28.5%
52-week range
Day change -₹8.85 (-1.6%) from ₹554 to ₹545 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in METROPOLIS, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Revenue grew 10.3% YoY
Concerns1
- Operating margin declining for 3 consecutive years (26.0% → 24.0% → 22.0%)
Rule-based from financial data. Not advice.
About the company
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally.
Read moreShow less
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.
- Sector
- Healthcare
- Shares outstanding
- 5.2 Cr shares
- ISIN
- INE112L01020
- BSE code
- 542650
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹9,882 Cr
- P/E
- 74.0x
- P/B
- 7.4x
- EV / EBITDA
- 36.5x
- EV / Sales
- 9.1x
- P/S
- 9.0x
- Earnings yield
- 1.4%
- 52-week high
- ₹601.90
- 52-week low
- ₹422.95
Profitability
- Operating margin
- 23.8%
- Net margin
- 10.5%
- EBITDA margin
- 24.9%
- ROE
- 11.3%
- ROCE
- 21.5%
- ROA
- 7.9%
- Dividend payout
- 18.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 7.6%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,217 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.3%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.6%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹275 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -6.8%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 7.8%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 0.7%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹269 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 13.0%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹6.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.7%
Solvency and efficiency
- Current ratio
- 1.43
- Debt / Equity
- 0.19
- Debt / Assets
- 0.13
- Debt / EBITDA
- 0.71
- Interest coverage
- 9.74
- Financial leverage
- 1.43
- CFO / Net profit
- 2.32
- Cash / Market cap
- 2.7%
- Cash per share
- ₹50.75
- Asset turnover
- 0.75
- Fixed asset turnover
- 0.98
- Capital intensity
- 1.02
- Debtor days
- 43 days
- Inventory turnover
- 6.52
- Cash conversion cycle
- -55 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹10 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹944 Cr |
| Sales | Operating profit | ₹273 Cr |
| Operating profit | Interest | ₹23 Cr |
| Operating profit | Depreciation | ₹105 Cr |
| Operating profit | Profit before tax | ₹145 Cr |
| Other income | Profit before tax | ₹17 Cr |
| Profit before tax | Tax and other | ₹37 Cr |
| Profit before tax | Net profit | ₹125 Cr |
Revenue and net profit
Revenue grew 10.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹816 Cr | ₹198 Cr |
| FY2022 | ₹1,157 Cr | ₹200 Cr |
| FY2023 | ₹1,066 Cr | ₹139 Cr |
| FY2024 | ₹1,103 Cr | ₹116 Cr |
| FY2025 | ₹1,217 Cr | ₹125 Cr |
Cash flows
FY2025: ₹275 Cr from operations, ₹79.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹202 Cr | ₹276 Cr |
| FY2022 | ₹244 Cr | -₹492 Cr |
| FY2023 | ₹238 Cr | ₹285 Cr |
| FY2024 | ₹269 Cr | ₹187 Cr |
| FY2025 | ₹275 Cr | ₹79 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,217 Cr+10.3%1Y
- Net profit
- ₹125 Cr+7.8%1Y
- Cash from operations
- ₹275 Cr
- Free cash flow
- ₹79 Cr-57.8%1Y
- Revenue CAGR, 5Y
- 10.6%
- EBITDA CAGR, 5Y
- 8.7%
- Net profit CAGR, 5Y
- 0.7%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,217 Cr | ₹273 Cr | — | ₹125 Cr | ₹275 Cr | ₹79 Cr | 10.0% | +10.3% | +7.8% |
Monthly returns
Month-by-month returns of METROPOLIS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹1,685 Cr |
| Equity capital | ₹10 Cr |
| Reserves | ₹1,234 Cr |
| Borrowings | ₹178 Cr |
| Other liabilities | ₹262 Cr |
| Assets | ₹1,685 Cr |
| Fixed assets | ₹1,129 Cr |
| Capital work in progress | ₹0 Cr |
| Investments | ₹321 Cr |
| Other assets | ₹235 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
METROPOLIS trades at 74.0x earnings against a peer median of 52.6x (a 41% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Metropolis Healthcare LimitedMETROPOLISthis companyP/E ↑ premium | ₹9,882 Cr | 74.0x | 7.4x | 11.3% | 36.5x |
| ALIVUS LIFE SCIENCES LIMITEDALIVUS | ₹10,777 Cr | 20.3x | 3.6x | 20.2% | 15.2x |
| Vijaya Diagnostic Centre LimitedVIJAYA | ₹10,297 Cr | 69.2x | 12.1x | 17.6% | 45.6x |
| Sanofi Consumer Healthcare India LimitedSANOFICONR | ₹9,742 Cr | 45.3x | 37.8x | — | — |
| JYOTHY LABS LIMITEDJYOTHYLAB | ₹9,555 Cr | 27.2x | 6.6x | 32.4% | 17.6x |
| HealthCare Global Enterprises LimitedHCG | ₹9,408 Cr | 513.0x | 8.0x | 2.8% | 49.9x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| Jeena Sikho Lifecare LimitedJSLL | ₹8,968 Cr | 58.2x | 25.2x | 35.9% | 90.3x |
| PROCTER & GAMBLE HEALTH LIMITEDPGHL | ₹8,946 Cr | 29.2x | 14.4x | — | — |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
METROPOLIS since 1 January, against earlier years.
Historical volatility
METROPOLIS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 30.0% |
| FY2022 | 28.0% |
| FY2023 | 26.0% |
| FY2024 | 24.0% |
| FY2025 | 22.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,217 Cr |
| Costs | |
| Interest | ₹23 Cr |
| Expenses | ₹944 Cr |
| Operating profitOperating Profit | ₹273 Cr |
| Other income and charges | |
| Profit before tax | ₹162 Cr |
| Tax | |
| Net profitNet Profit | ₹125 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹1,685 Cr |
| Equity capitalEquity Capital | ₹10 Cr |
| Reserves | ₹1,234 Cr |
| Borrowings | ₹178 Cr |
| Other liabilitiesOther Liabilities | ₹262 Cr |
| AssetsTotal Assets | ₹1,685 Cr |
| Fixed assetsFixed Assets | ₹1,129 Cr |
| Capital work in progressCWIP | ₹0 Cr |
| Investments | ₹321 Cr |
| Other assetsOther Assets | ₹235 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹275 Cr |
| Investing cash flowCash from Investing Activity | -₹196 Cr |
| Financing cash flowCash from Financing Activity | -₹84 Cr |
| Change in cashNet Cash Flow | -₹6 Cr |
Learn while you research
Academy chapters picked for Metropolis Healthcare Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 74.0, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read